Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter Variable Length Study to Assess the Efficacy and Safety of PT010 Relative to PT009 and Symbicort in Adult and Adolescent Participants With Inadequately Controlled Asthma

Next Previous
Trial Profile

A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter Variable Length Study to Assess the Efficacy and Safety of PT010 Relative to PT009 and Symbicort in Adult and Adolescent Participants With Inadequately Controlled Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol/glycopyrrolate (Primary) ; Budesonide/formoterol; Prednisolone; Salbutamol
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms LOGOS
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 24 Jul 2026 According to AstraZeneca media release, company has been recommended for approval in the European Union (EU) for the maintenance treatment of asthma in patients 12 years of age and older who are not adequately controlled by combination of a medium dose inhaled corticosteroid and long acting beta 2 agonist based upon KALOS and LOGOS study.
  • 28 Apr 2026 According to AstraZeneca media release, based on results from KALOS and LOGOS trials the U.S FDA has approved the fixed-dose triple-combination therapy Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) in the US for the maintenance treatment of asthma in adult and paediatric patients 12 years of age and older.
  • 28 Apr 2026 Results presented in the AstraZeneca media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top